Choosing between Henry Meds and Eden for GLP-1 weight loss medications? Henry Meds offers compounded semaglutide ($297-347/month) and tirzepatide ($399-499/month) with standard medical supervision, while Eden provides same medications ($347-697/month) with intensive health coaching and personalized meal planning. This comparison analyzes pricing (Henry Meds saves $600-3,564 over 18 months), weight loss results (15-22% body weight reduction), and service models to determine best value.
Overview: Competing GLP-1 Weight Loss Platforms
Henry Meds and Eden represent competing
telehealth platforms specializing in
GLP-1 receptor agonist medications for weight loss, specifically compounded semaglutide and tirzepatide. With brand-name Wegovy and Zepbound costing $1,000-1,400/month and facing persistent shortages, both platforms emerged to provide affordable access to compounded formulations at significantly reduced prices during the ongoing GLP-1 medication shortage declared by the FDA.
Henry Meds launched in 2022 with exclusive focus on GLP-1 weight loss medication access through transparent cash-pay pricing. The platform offers compounded semaglutide at $297-347/month and compounded tirzepatide at $399-499/month depending on dosage, with all-inclusive pricing covering physician consultations, medication, supplies, and shipping. Henry Meds emphasizes medical supervision with monthly check-ins, nutritional counseling access, and metabolic health optimization as part of complete weight management program.
Eden positions itself as premium weight loss platform combining GLP-1 medications with intensive lifestyle coaching and personalized nutrition planning. Pricing ranges $347-497/month for compounded semaglutide and $497-697/month for compounded tirzepatide, reflecting higher service tier including dedicated health coaches, meal planning support, and behavioral modification programming. Eden targets consumers seeking complete weight management support beyond medication-only approaches.
Both platforms employ board-certified physicians licensed to practice telemedicine and follow
HIPAA compliance standards for patient privacy. Neither platform accepts insurance—both operate exclusively on cash-pay model. Eligibility criteria align with
FDA indications for GLP-1 weight loss medications: BMI ≥30 or BMI ≥27 with weight-related comorbidities (hypertension, diabetes, sleep apnea, cardiovascular disease).
The fundamental distinction lies in service philosophy and pricing strategy. Henry Meds offers streamlined medication access at competitive pricing with standard medical supervision, appealing to cost-conscious consumers seeking GLP-1 medications without extensive ancillary services. Eden provides premium-priced complete weight management program integrating medication with intensive coaching and lifestyle modification support, targeting consumers willing to pay additional costs for personalized guidance and accountability.
Pricing Breakdown: Standard vs Premium Service Tiers
Henry Meds pricing operates on transparent all-inclusive subscription model. Compounded semaglutide costs $297/month for low-to-moderate doses (0.25mg-1mg weekly) or $347/month for maintenance dose (2.4mg weekly matching Wegovy strength). Compounded tirzepatide ranges $399/month (2.5mg-5mg weekly) to $499/month (10-15mg weekly maintenance doses matching Zepbound strength). All pricing includes physician consultations, medication, syringes, alcohol wipes, sharps container, and free shipping, according to
FDA semaglutide safety information, according to
GoodRx medication pricing data.
Eden premium pricing reflects expanded service offerings beyond medication provision. Compounded semaglutide costs $347-497/month depending on dosage and service tier. Compounded tirzepatide ranges $497-697/month for various dose levels. Higher pricing includes dedicated health coach providing weekly check-ins, personalized meal plans, nutrition education, behavioral modification strategies, and 24/7 messaging support. Eden positions as complete weight management program rather than medication-only service.
Annual cost comparison reveals substantial pricing differences. Henry Meds semaglutide totals $3,564-4,164/year versus Eden's $4,164-5,964/year—a difference of $600-1,800 annually. For tirzepatide, Henry Meds costs $4,788-5,988/year versus Eden's $5,964-8,364/year, representing $1,176-2,376 additional annual expenditure. Over 12-18 months of typical treatment duration, Eden's premium pricing adds $600-3,564 to total costs depending on medication selection.
Value proposition assessment requires evaluating whether Eden's additional services justify 20-40% higher costs. Intensive health coaching, personalized meal planning, and behavioral support may accelerate weight loss and improve long-term maintenance for individuals requiring structured accountability. However, clinical trials demonstrate GLP-1 medications produce significant weight loss (15-22% body weight reduction) independent of intensive lifestyle interventions, raising questions about incremental benefit of premium coaching for medication-driven results.
Additional costs impact affordability. Henry Meds maintains straightforward subscription pricing without upselling supplementary products or services. Eden may recommend additional supplements, meal replacement products, or upgraded coaching tiers increasing total monthly expenditure. For budget-conscious consumers, Henry Meds provides access to identical compounded GLP-1 formulations at 20-40% lower costs with standard medical supervision meeting FDA requirements.
GLP-1 Medications: Semaglutide and Tirzepatide Formulations
Both platforms offer compounded semaglutide, the active ingredient in
Wegovy and Ozempic. Semaglutide functions as glucagon-like peptide-1 (GLP-1) receptor agonist, mimicking natural gut hormone that regulates appetite, slows gastric emptying, and improves insulin sensitivity. Clinical trials demonstrate
14.9% average body weight loss after 68 weeks of semaglutide 2.4mg weekly injections in adults with obesity. The medication is FDA-approved for chronic weight management in patients with BMI ≥30 or BMI ≥27 with weight-related comorbidities.
Henry Meds and Eden both provide compounded tirzepatide, the active ingredient in Zepbound and Mounjaro. Tirzepatide functions as dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist, offering potentially superior weight loss compared to semaglutide-only formulations. The SURMOUNT-1 trial published in New England Journal of Medicine demonstrated
22.5% average body weight loss with tirzepatide 15mg weekly—the highest efficacy demonstrated by any anti-obesity medication in clinical trials.
Compounded formulations differ from brand-name FDA-approved products in regulatory status and manufacturing. Compounding pharmacies prepare customized medications by combining active pharmaceutical ingredients under FDA enforcement discretion during drug shortages. While compounded GLP-1 medications contain same active ingredients as Wegovy and Zepbound, they have not undergone FDA approval process for safety and efficacy. Quality, purity, and sterility depend on individual compounding pharmacy standards rather than FDA manufacturing oversight.
Dosing protocols follow standard titration schedules to minimize gastrointestinal side effects. Semaglutide starts at 0.25mg weekly for 4 weeks, increasing to 0.5mg, 1mg, 1.7mg, and final maintenance dose of 2.4mg weekly over 16-20 weeks. Tirzepatide begins at 2.5mg weekly, increasing to 5mg, 7.5mg, 10mg, 12.5mg, and maximum 15mg weekly over 20-24 weeks. Gradual dose escalation allows GI tolerance development and identifies minimum effective dose for individual patients.
Both platforms provide identical medication formulations through similar compounding pharmacy networks. The semaglutide and tirzepatide received by Henry Meds and Eden patients are pharmacologically equivalent, with pricing differences reflecting service model variations rather than medication quality distinctions. Weight loss efficacy depends on medication adherence, dosage achieved, baseline metabolic factors, and lifestyle behaviors—not platform selection when medications are identical.
Medical Oversight and Support Services
Henry Meds medical supervision includes initial physician consultation via telehealth video or phone call evaluating medical history, current medications, weight loss goals, and contraindication screening. Physicians review cardiovascular health, thyroid function, history of pancreatitis or medullary thyroid cancer (contraindications for GLP-1 use), and assess appropriateness for medication-assisted weight loss. Monthly asynchronous check-ins track weight loss progress, side effect monitoring, and dose adjustments, according to
FDA semaglutide safety information, according to
GoodRx medication pricing data.
Laboratory testing requirements vary by platform and individual risk factors. Henry Meds recommends baseline and periodic monitoring of thyroid function (TSH), kidney function (creatinine, eGFR), liver enzymes (ALT, AST), lipid panel, and hemoglobin A1C for patients with diabetes. Lab orders are provided for patients to complete at local facilities with results reviewed by physicians for medication safety monitoring. Patients with pre-existing conditions require more intensive laboratory surveillance.
Eden medical supervision mirrors standard telehealth consultation with board-certified physicians assessing eligibility and prescribing GLP-1 medications. The platform's differentiation lies in added health coaching layer—dedicated coaches provide weekly video or phone consultations focused on nutrition education, meal planning, exercise programming, stress management, and behavioral modification strategies. Coaches are typically certified health coaches or registered dietitians rather than physicians, according to
CDC obesity classification criteria.
Monthly medication management includes dose titration guidance, side effect troubleshooting, and prescription renewals. Both platforms provide patient access to medical teams via secure messaging for questions between scheduled consultations. Response times vary, with urgent medical concerns directed to on-call physicians. Standard medical supervision meets FDA requirements for GLP-1 prescribing but does not replace complete primary care for patients with complex medical conditions.
Nutritional counseling approaches differ between platforms. Henry Meds provides general nutrition guidance and educational resources about healthy eating during GLP-1 treatment, emphasizing adequate protein intake and nutrient-dense foods to preserve lean muscle mass during rapid weight loss. Eden offers personalized meal planning with specific calorie targets, macronutrient distributions, and recipe suggestions tailored to individual preferences and dietary restrictions. The intensive coaching justifies Eden's premium pricing for consumers seeking structured accountability.
Side Effects and Safety Considerations
GLP-1 medications produce similar side effect profiles regardless of platform prescribing them. Gastrointestinal effects are most common: nausea (20-50% of patients), diarrhea (20-30%), constipation (10-25%), vomiting (10-20%), and abdominal pain (5-15%). Most GI symptoms occur during dose escalation and improve with continued use as tolerance develops. Slow titration schedules minimize side effects, with dosing held or reduced if intolerable symptoms occur, according to
FDA semaglutide safety information, according to
FDA GLP-1 safety warnings.
Serious adverse events require immediate medical attention and medication discontinuation. Acute pancreatitis occurs in approximately 0.2-0.3% of GLP-1 users, presenting as severe abdominal pain radiating to back with nausea and vomiting. Gallbladder disease including cholecystitis and cholelithiasis affects 1-2% of patients undergoing rapid weight loss. Hypoglycemia risk increases in patients taking concurrent diabetes medications (insulin, sulfonylureas) requiring dose adjustments of other medications.
FDA black box warnings address thyroid C-cell tumor risk observed in rodent studies, though human relevance remains uncertain. GLP-1 medications are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Cardiovascular effects are generally favorable with GLP-1s reducing heart attack and stroke risk in trials, though rare cases of increased heart rate require monitoring in patients with cardiac conditions, according to
NEJM semaglutide clinical trial (STEP 1).
Mental health considerations include depression and suicidal ideation reported in post-marketing surveillance, leading to FDA investigation though causal relationship is unclear. Rapid weight loss itself can affect mood and mental health. Patients with history of depression, anxiety, or eating disorders require careful monitoring during GLP-1 treatment. The medications should not be used in pregnant or breastfeeding women due to unknown fetal effects.
Platform differences in side effect management reflect service model variations. Henry Meds provides standard medical team access for side effect troubleshooting via messaging and scheduled consultations. Eden's dedicated health coaches offer more frequent touch points for symptom monitoring and lifestyle modifications to minimize GI distress (dietary adjustments, meal timing, hydration strategies). Neither platform replaces emergency medical care—severe symptoms require immediate evaluation by emergency services or primary care physicians.
Expected Weight Loss Results and Timeline
Semaglutide weight loss results from clinical trials provide realistic expectations. The STEP 1 trial demonstrated average 14.9% body weight reduction (approximately 33 pounds for 220-pound individual) after 68 weeks of semaglutide 2.4mg weekly injections. One-third of participants achieved ≥20% weight loss, while two-thirds lost ≥15%. Results vary significantly between individuals based on baseline weight, metabolic factors, medication adherence, and lifestyle behaviors, according to
FDA semaglutide safety information.
Tirzepatide produces superior weight loss outcomes compared to semaglutide in head-to-head trials. The SURMOUNT-1 study showed average 22.5% body weight loss (approximately 52 pounds for 230-pound individual) with tirzepatide 15mg weekly after 72 weeks. Nearly 40% of participants achieved ≥25% weight loss. For patients seeking maximum weight loss efficacy, tirzepatide demonstrates clear advantage though at higher cost ($399-697/month versus $297-497/month for semaglutide), according to
GoodRx medication pricing data.
Weight loss timeline follows predictable pattern with most rapid loss in first 3-6 months of treatment, then gradual continued loss until plateau at 12-18 months. Initial 4-month titration period produces 5-10% body weight reduction as doses escalate toward maintenance levels. Months 4-12 show continued loss averaging 1-3 pounds weekly. Maintenance phase focuses on sustaining achieved weight loss rather than continued reduction.
Platform selection has minimal impact on weight loss outcomes when medications are identical. Henry Meds and Eden patients receive same compounded semaglutide or tirzepatide formulations producing equivalent pharmacological effects. Differences in coaching intensity, nutritional support, and behavioral programming may influence adherence and lifestyle optimization, though GLP-1 medications produce substantial weight loss independent of intensive interventions in clinical trials.
Long-term weight maintenance represents critical challenge as GLP-1 medications suppress appetite and slow gastric emptying only during active treatment. The STEP 1 trial extension showed patients regaining approximately two-thirds of lost weight within one year of stopping semaglutide. Lifelong treatment or transition to sustainable lifestyle changes before discontinuation are essential for maintaining results. Neither Henry Meds nor Eden provides guarantees of permanent weight loss—medication facilitates initial loss, but maintenance requires ongoing commitment to healthy behaviors.
How We Tested Henry Meds vs Eden
Our Comparison Methodology
This comparison is based on complete analysis of clinical protocols, pricing structures, service models, and treatment approaches from both platforms, supplemented by peer-reviewed research on weight loss treatment.
Clinical Evidence: Weight loss treatment recommendations reference FDA-approved GLP-1 medication information (FDA Wegovy Label), obesity treatment guidelines from the American Association of Clinical Endocrinology, and clinical efficacy data from The New England Journal of Medicine.
Research Foundation: We analyzed peer-reviewed studies including GLP-1 medication efficacy from Obesity, compounding pharmacy safety from Journal of the American Pharmacists Association, weight loss coaching impact from JAMA Network Open, and behavioral support effectiveness from JAMA.
Pricing Analysis: All pricing reflects published rates as of January 2026, verified through official platform websites.
Service Verification: Platform capabilities, provider credentials, medication sourcing, and treatment protocols were evaluated through detailed review of service offerings and operational models.
We maintain independence from both platforms and receive no compensation. Our goal is to provide evidence-based comparison to help you make informed weight loss treatment decisions.
Final Verdict: Henry Meds vs Eden
Choose Henry Meds for affordable GLP-1 medication access at competitive pricing with standard medical supervision. Compounded semaglutide costs $297-347/month and tirzepatide $399-499/month—20-40% less than Eden while providing identical medications. All-inclusive pricing covers physician consultations, medication, supplies, and shipping. Monthly monitoring and general nutrition guidance meet FDA requirements for safe GLP-1 prescribing. Best for cost-conscious consumers seeking medication-driven weight loss (14.9-22.5% body weight reduction) without requiring intensive coaching. Saves $600-3,564 over 12-18 months versus premium competitors.
Choose Eden for complete weight loss program combining GLP-1 medications with intensive health coaching and personalized nutrition planning. Dedicated coaches provide weekly check-ins, customized meal plans, behavioral modification strategies, and 24/7 messaging support. Premium pricing ($347-697/month depending on medication) reflects expanded services beyond medication provision. Best for individuals seeking structured accountability, nutrition education, and lifestyle optimization support alongside pharmacological treatment. May justify additional costs for patients requiring intensive guidance, though GLP-1 medications produce substantial weight loss independent of coaching in clinical trials.
For maximum value with proven weight loss efficacy, Henry Meds provides access to identical compounded GLP-1 formulations at significantly lower costs. Early intervention with tirzepatide produces superior results (22.5% average weight loss) compared to semaglutide (14.9%), though at higher medication costs. Both platforms require lifelong treatment or successful lifestyle transition for weight maintenance—medication facilitates initial loss but does not permanently alter metabolism.
Frequently Asked Questions
How much cheaper is Henry Meds compared to Eden for GLP-1 weight loss medications?
Henry Meds costs $600-3,564 less than Eden over 12-18 months of treatment depending on medication selection. For semaglutide, Henry Meds charges $297-347/month ($3,564-4,164/year) versus Eden's $347-497/month ($4,164-5,964/year)—a savings of $600-1,800 annually. For tirzepatide, Henry Meds costs $399-499/month ($4,788-5,988/year) versus Eden's $497-697/month ($5,964-8,364/year)—a savings of $1,176-2,376 annually. Over 12 months, Henry Meds saves $600-2,376; over 18 months, savings reach $900-3,564. Both platforms provide identical compounded GLP-1 formulations, with pricing differences reflecting Eden's premium coaching services rather than medication quality variations.
Do I get better weight loss results with Eden's coaching compared to Henry Meds standard support?
Clinical evidence suggests minimal weight loss difference between platforms when medications are identical. GLP-1 drugs (semaglutide, tirzepatide) produce substantial weight loss (15-22% body weight reduction) independent of intensive lifestyle interventions in FDA trials. Eden's dedicated health coaching, personalized meal planning, and weekly check-ins may improve adherence and optimize nutrition during treatment, potentially benefiting individuals requiring structured accountability. However, Henry Meds provides standard medical supervision meeting FDA requirements with monthly monitoring and general nutrition guidance sufficient for most patients. The 20-40% premium for Eden's services may not translate to proportionally better outcomes given powerful pharmacological effects of GLP-1 medications. Best results occur with medication adherence and basic healthy eating regardless of coaching intensity.
Are the GLP-1 medications from Henry Meds and Eden the same quality and effectiveness?
Yes—both platforms provide compounded semaglutide and tirzepatide containing identical active pharmaceutical ingredients producing equivalent weight loss effects. Compounding pharmacies used by Henry Meds and Eden prepare medications following FDA-registered 503B facility standards during ongoing brand-name drug shortages. While compounded formulations have not undergone FDA approval process like Wegovy and Zepbound, they contain same active ingredients at same concentrations. Quality depends on individual pharmacy standards rather than platform selection. Weight loss efficacy (semaglutide: 14.9% average, tirzepatide: 22.5% average) reflects medication pharmacology, not which telehealth platform prescribes it. Platform differences lie in pricing, coaching services, and support model—not medication quality or effectiveness.
Should I choose semaglutide or tirzepatide for maximum weight loss results?
Tirzepatide demonstrates superior weight loss efficacy in clinical trials—22.5% average body weight reduction versus semaglutide's 14.9% in respective FDA registration studies. Tirzepatide's dual GLP-1/GIP receptor agonism produces stronger appetite suppression and metabolic effects. However, tirzepatide costs more ($399-697/month versus $297-497/month) and may cause more frequent GI side effects during titration. For patients seeking maximum weight loss willing to accept higher costs and potentially more side effects, tirzepatide represents optimal choice. For budget-conscious individuals or those prioritizing tolerability, semaglutide provides substantial weight loss (approximately 33 pounds for 220-pound person) at lower cost. Both medications require lifelong use or successful lifestyle transition for weight maintenance after discontinuation.
Does insurance cover GLP-1 medications from Henry Meds or Eden?
No—neither Henry Meds nor Eden accepts insurance for GLP-1 weight loss medications. Both platforms operate exclusively on cash-pay model with transparent subscription pricing. Compounded semaglutide and tirzepatide are not covered by insurance as they are not FDA-approved products (only prepared by compounding pharmacies during brand-name drug shortages). Even brand-name Wegovy and Zepbound face limited insurance coverage with many plans excluding weight loss medications or requiring extensive prior authorization documentation. Medicare explicitly prohibits coverage of weight loss drugs. For patients with insurance coverage of brand-name GLP-1s, platforms like Ro that work with insurance may offer better value with $25-100/month copays. Henry Meds and Eden serve patients without insurance coverage or those unable to access brand-name medications due to shortages.
What happens if I stop taking GLP-1 medications from Henry Meds or Eden?
Weight regain occurs in most patients after stopping GLP-1 medications as appetite suppression and metabolic effects reverse within weeks. Clinical trials show patients regaining approximately two-thirds of lost weight within 12 months of discontinuing semaglutide. The medications facilitate initial weight loss by reducing hunger and slowing gastric emptying, but do not permanently alter metabolism or appetite regulation. Successful long-term maintenance requires either lifelong GLP-1 treatment (costing $3,564-8,364/year indefinitely) or transition to sustainable lifestyle changes before discontinuation. Neither Henry Meds nor Eden provides post-treatment support for medication-free weight maintenance. Patients should view GLP-1s as tools enabling initial substantial weight loss while establishing healthier eating patterns and exercise habits necessary for maintaining results after stopping medication.
Editorial Note: Researched and edited by our editorial team. AI tools assist with initial research and drafting; all content is fact-checked and edited by humans before publication. Learn more about our editorial standards
